Sugi Predict

Sugi Predict / Compounds / SCHEMBL17048525

SCHEMBL17048525

SCHEMBL17048525

COc1ccc(CN(c2ncns2)S(=O)(=O)c2ccc(Oc3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 5/20 0.43
▸ BMP1 P13497 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ PGR P06401 2/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ MMP1 P03956 2/20 0.34
▸ MMP9 P14780 2/20 0.34
▸ MMP13 P45452 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ SCN3A Q9NY46 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ MDM2 Q00987 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18882671 0.95 SCN9A (0.41) SCN9ABMP1GAAPGRNR3C1
SCHEMBL17048544 0.91 SCN9A (0.42) SCN9ABMP1GAASCN5AMDM2
SCHEMBL17048606 0.90 SCN9A (0.42) SCN9AGAAALDH1A1LMNASCN3A
SCHEMBL17048636 0.88 SLC22A12 (0.42) SCN9ASCN5A
SCHEMBL17048624 0.87 SCN9A (0.37) SCN9AGAA
SCHEMBL18882676 0.87 SCN9A (0.40) SCN9AGAAMMP1MMP9MMP13
SCHEMBL17048537 0.86 BMP1 (0.39) SCN9ABMP1GAAPGRNR3C1
SCHEMBL18882683 0.86 SCN9A (0.40) SCN9AGAAALDH1A1LMNASCN3A
SCHEMBL17056209 0.86 SCN9A (0.35) SCN9AGAAALDH1A1LMNASCN5A
SCHEMBL17048645 0.85 SCN9A (0.49) SCN9ATP53CNR1CNR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236078-B2 Heterocyclic inhibitors of the sodium channel DeGiacomo, Mark G. (US) 2022-02-01 — — US disclosed
US-11236078-B2 Heterocyclic inhibitors of the sodium channel DeGiacomo, Mark G. (US) 2022-02-01 — — US disclosed
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL DeGiacomo, Mark G. (US) 2017-05-25 — — US disclosed
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL DeGiacomo, Mark G. (US) 2017-05-25 — — US disclosed
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL DeGiacomo, Mark G. (US) 2017-05-25 — — US disclosed
WO-2015130957-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL Zalicus Pharmaceuticals, Ltd. (US) 2015-09-03 — — WO disclosed
WO-2015130957-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL Zalicus Pharmaceuticals, Ltd. (US) 2015-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145003-A1 HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL SCN1B, SCN1A, CACNA1S SCN9A 29/4885BMP1 1993/4885GAA 1797/4885
US-11236078-B2 Heterocyclic inhibitors of the sodium channel SCN1B, TRPM6, SCN1A SCN9A 32/4885BMP1 2319/4885GAA 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.